InterNatIonal CHildhood Leukemia Microbiome/MEtabolome Cohort
NCT ID: NCT05929976
Last Updated: 2025-07-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
4900 participants
OBSERVATIONAL
2022-10-26
2029-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Oronasal Microbiota in Pediatric Oncology Patients
NCT02949427
Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia
NCT01057290
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
NCT01433965
Metabolic Syndrome in Young Patients With Acute Lymphoblastic Leukemia in Remission
NCT00801346
Laboratory Study of Lymphoblasts in Young Patients With High-Risk Acute Lymphoblastic Leukemia
NCT00896766
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
No intervention
No intervention
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients must have newly diagnosed B- or T-cell ALL, or mixed phenotype acute leukemia confirmed by pathology report.
* Patients must be receiving treatment at one of the participating centers.
Exclusion Criteria
3 Years
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
International Agency for Research on Cancer
OTHER
Columbia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Elena Ladas
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Columbia University Irving Medical Center
New York, New York, United States
Hospital de Cancer Infanto Juvenil de Barretos
Barretos, , Brazil
Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)
Recife, , Brazil
Instituto de Tratamento do Câncer Infantil (ITACI)
São Paulo, , Brazil
Unidad Nacional De Oncologia Pediatrica
Guatemala City, , Guatemala
Hospital Escuela
Tegucigalpa, , Honduras
Post-Graduate Institute of Medical Education and Research (PGIMER)
Chandigarh, , India
Muhumbili Hospital
Dar es Salaam, Dar es Salaam Region, Tanzania
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AAAU1407
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.